Emergent BioSolutions rises on disclosing $400 mln in orders through 2025
25/09/2024 13:21
** Shares of Emergent BioSolutions EBS.N rise 12.6% to
$6.88 premarket
** Co says it has secured about $400 mln in orders for 2024
and 2025 for its vaccinia virus, smallpox and mpox vaccines
** EBS says this includes the previously disclosed contract
from the U.S. government to procure the vaccines, valued at more
than $250 mln
** Says to date in 2024, customer orders of nearly $210 mln
have been delivered for ACAM2000 - its smallpox and mpox vaccine
- and CNJ-016 - its vaccine for vaccinia virus
** For the remainder of 2024 and into 2025, co says it is
confirmed to deliver over $185 mln in ACAM2000 and CNJ-016
orders
** Up to last close, stock more than doubled YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))